mAbxience and Egis Enter Strategic License Agreement for Biosimilar Candidates in Key Central and Eastern European MarketsMiguel Martínez-Cava2024-11-12T08:59:05+01:00November 12, 2024|Press releases|
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar CandidateMiguel Martínez-Cava2024-10-03T14:33:04+02:00October 3, 2024|Press releases|
mAbxience Appoints Jurgen Van Broeck as New CEOMiguel Martínez-Cava2024-05-09T09:42:26+02:00May 9, 2024|Press releases|
The blueprint for successful CDMO partnershipsadriana.polo2024-12-23T13:03:15+01:00December 23, 2024|News|
From lab to market: mAbxience’s approach to biopharmaceutical developmentadriana.polo2024-12-02T12:04:35+01:00December 2, 2024|News|
Biosimilar production: challenges and strategiesadriana.polo2024-11-19T11:06:10+01:00November 19, 2024|News|
